International Niemann–Pick Disease Alliance
ALACHUA, FL – (Marketwired – June 13, 2017) – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that Ms. Jacqueline Imrie, a pediatric nurse (retired) based in the U.K., and Ms. Shannon Reedy, a Niemann-Pick Disease Type C (NPC) parent and advocate based in the U.S., are joining the Company as consultants to assist in helping patients and families understand and access both of CTD’s clinical trials evaluating its proprietary formulation of hydroxypropyl betacyclodextrin, Trappsol® Cyclo™, to treat NPC, a rare and fatal genetic disease that damages the brain, lung, liver, spleen, and other organs. CTD is currently recruiting for a Phase I study in the U.S. and a Phase I/II clinical trial in the EU.
CTD’s Chairman and CEO, N. Scott Fine, said, “We are receiving a growing number of requests for information about our clinical trials. We look forward to working with both Ms. Reedy and Ms. Imrie to assist us as we share information on our trials with the NPC community.”
Ms. Imrie received her training as a pediatric nurse, then in biochemistry and genetics, then as a genetics counselor. She spent 20 years at the Willink Metabolic Unit of Manchester Hospital, Manchester, UK. In retirement, Ms. Imrie worked with the leading NPC family support organization, Niemann Pick UK, to create a national database for NPC and to raise awareness of the disease with physicians and other health care professionals to aid in quicker diagnoses.
Ms. Reedy has been a leading advocate in the NPC community since 2009, when her two-year old son, Chase, received the diagnosis. Ms. Reedy obtained one of the first approvals for NPC compassionate use with Trappsol® Cyclo™ in the U.S. Ms. Reedy has continued to help U.S. families with new NPC diagnoses as they evaluate treatment options even after Chase succumbed to the disease in December 2016.
Additionally, Dr. Caroline Hastings, UCSF Benioff Children’s Hospital Oakland, and Principal Investigator for the U.S. trial and Senior Clinical Advisor to the EU trial, has also been a resource for patients and families globally since 2009 when she was the first physician in the U.S. to provide Trappsol® Cyclo™ to patients in a compassionate use protocol. Dr. Hastings will continue to be a source of information for NPC families and physicians interested in CTD’s U.S. and EU trials.
“We encourage patients, families and caregivers to reach out to Dr. Hastings, Ms. Reedy and Ms. Imrie to learn more about our trials. They are all excellent sources of information on our clinical programs, as well as on the disease more broadly,” said Dr. Sharon Hrynkow, CTD’s Senior Vice President for Medical Affairs.
Dr. Caroline Hastings, Principal Investigator for the US trial and Senior Clinical Advisor to the EU study; chastings@mail.cho.org
Ms. Jackie Imrie, Liaison to CTD for patients and families (US and EU), UK-based; jackie@npuk.org; 00447414529392 – please note time zone.
Ms. Shannon Reedy, Liaison to CTD for patients and families (US and EU), US-based; shannon.reedy@hotmail.com
For further information on the clinical trials, see ClinicalTrials.Gov (NCT 02939547 and NCT 02912793) as well as CTD’s website at www.ctd-holdings.com, including Frequently Asked Questions at http://www.ctd-holdings.com/cyclodextrins/faq
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company’s website: www.ctd-holdings.com
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568 Hans@lifesciadvisors.com